EA202092908A1 - Модуляторы ионных каналов - Google Patents
Модуляторы ионных каналовInfo
- Publication number
- EA202092908A1 EA202092908A1 EA202092908A EA202092908A EA202092908A1 EA 202092908 A1 EA202092908 A1 EA 202092908A1 EA 202092908 A EA202092908 A EA 202092908A EA 202092908 A EA202092908 A EA 202092908A EA 202092908 A1 EA202092908 A1 EA 202092908A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ion channel
- disease
- treating
- condition associated
- channel modulators
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 abstract 2
- 102000018674 Sodium Channels Human genes 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000007547 Dravet syndrome Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738508P | 2018-09-28 | 2018-09-28 | |
| PCT/US2019/034653 WO2019232209A1 (en) | 2018-05-30 | 2019-05-30 | Ion channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092908A1 true EA202092908A1 (ru) | 2021-05-14 |
Family
ID=69949703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092908A EA202092908A1 (ru) | 2018-09-28 | 2019-05-30 | Модуляторы ионных каналов |
| EA202190879A EA202190879A1 (ru) | 2018-09-28 | 2019-09-27 | Модуляторы ионных каналов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190879A EA202190879A1 (ru) | 2018-09-28 | 2019-09-27 | Модуляторы ионных каналов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12479844B2 (enExample) |
| EP (1) | EP3856193A4 (enExample) |
| JP (2) | JP7576539B2 (enExample) |
| KR (1) | KR102842377B1 (enExample) |
| CN (1) | CN113573713A (enExample) |
| AU (2) | AU2019346635A1 (enExample) |
| BR (1) | BR112021005913A2 (enExample) |
| CA (1) | CA3142470A1 (enExample) |
| EA (2) | EA202092908A1 (enExample) |
| IL (1) | IL281946A (enExample) |
| MX (1) | MX2021003634A (enExample) |
| WO (1) | WO2020069322A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| MX2020012838A (es) | 2018-05-30 | 2021-07-16 | Praxis Prec Medicines Inc | Moduladores de los canales ionicos. |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| PE20221280A1 (es) | 2019-11-27 | 2022-09-05 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos |
| US20250145637A1 (en) | 2021-08-10 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co. Ltd. | Sulfonamide derivative, preparation method therefor and medical use thereof |
| KR20250005348A (ko) | 2022-04-26 | 2025-01-09 | 프락시스 프리시젼 메디신즈, 인크. | 신경 장애의 치료 |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| KR20250173086A (ko) | 2024-05-31 | 2025-12-10 | 더웨이브컨설팅 주식회사 | 이온 채널 조절 활성을 갖는 반도비탈거미 유래 펩타이드 및 이의 용도 |
| WO2026082004A1 (zh) * | 2024-10-14 | 2026-04-23 | 上海京新生物医药有限公司 | 稠合杂芳基衍生物及其制备方法与应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| CA1080712A (en) | 1976-09-22 | 1980-07-01 | Jay D. Albright | Hypotensive agents |
| US4112095A (en) | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
| US4242515A (en) * | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9507348D0 (en) | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
| WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2006061428A2 (en) | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| EP1904630A4 (en) | 2005-06-16 | 2009-10-21 | Bionomics Ltd | METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE |
| HRP20170103T1 (hr) | 2005-12-21 | 2017-03-24 | Janssen Pharmaceutica N.V. | Triazolopiridazini kao modulatori tirozin kinaze |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| KR100858357B1 (ko) | 2006-10-02 | 2008-09-11 | (주) 디지탈바이오텍 | 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| US20100125091A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
| MX342128B (es) | 2008-12-24 | 2016-09-14 | Bial - Portela & C A S A | Compuestos farmaceuticos. |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| ES2642586T3 (es) * | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| FR2953520B1 (fr) | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| WO2012151136A1 (en) | 2011-05-03 | 2012-11-08 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| WO2013043925A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| WO2013045519A1 (en) | 2011-09-27 | 2013-04-04 | Genfit | Derivatives of 6-substituted triazolopyridazines as rev-erb agonists |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| WO2014179492A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| DK3035926T3 (da) | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| NZ720651A (en) | 2013-12-19 | 2017-12-22 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| ES2912073T3 (es) | 2014-06-20 | 2022-05-24 | Mitsubishi Chem Corp | Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| AU2015279377B2 (en) | 2014-06-26 | 2019-09-12 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
| JP2017001991A (ja) | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | 新規ベンズオキサゾロン化合物 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2018098500A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| EA201991306A1 (ru) | 2017-08-30 | 2020-03-20 | Праксис Пресижн Медсинз, Инк. | Соединения и способы их применения |
| MX2020012838A (es) | 2018-05-30 | 2021-07-16 | Praxis Prec Medicines Inc | Moduladores de los canales ionicos. |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| CN114980899A (zh) | 2019-11-26 | 2022-08-30 | 普拉西斯精密医药公司 | 离子通道调节剂 |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| PE20221280A1 (es) | 2019-11-27 | 2022-09-05 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos |
-
2019
- 2019-05-30 EA EA202092908A patent/EA202092908A1/ru unknown
- 2019-09-27 JP JP2021517348A patent/JP7576539B2/ja active Active
- 2019-09-27 AU AU2019346635A patent/AU2019346635A1/en not_active Abandoned
- 2019-09-27 BR BR112021005913-0A patent/BR112021005913A2/pt unknown
- 2019-09-27 US US17/280,485 patent/US12479844B2/en active Active
- 2019-09-27 WO PCT/US2019/053467 patent/WO2020069322A1/en not_active Ceased
- 2019-09-27 CN CN201980078653.2A patent/CN113573713A/zh active Pending
- 2019-09-27 EA EA202190879A patent/EA202190879A1/ru unknown
- 2019-09-27 MX MX2021003634A patent/MX2021003634A/es unknown
- 2019-09-27 KR KR1020217012574A patent/KR102842377B1/ko active Active
- 2019-09-27 CA CA3142470A patent/CA3142470A1/en active Pending
- 2019-09-27 EP EP19865432.9A patent/EP3856193A4/en active Pending
-
2021
- 2021-03-31 IL IL281946A patent/IL281946A/en unknown
-
2024
- 2024-01-04 JP JP2024000336A patent/JP2024019735A/ja active Pending
-
2025
- 2025-05-29 AU AU2025204027A patent/AU2025204027A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113573713A (zh) | 2021-10-29 |
| EP3856193A4 (en) | 2022-08-31 |
| AU2025204027A9 (en) | 2026-03-19 |
| JP2022502442A (ja) | 2022-01-11 |
| JP2024019735A (ja) | 2024-02-09 |
| US12479844B2 (en) | 2025-11-25 |
| CA3142470A1 (en) | 2020-04-02 |
| EP3856193A1 (en) | 2021-08-04 |
| KR20210113974A (ko) | 2021-09-17 |
| MX2021003634A (es) | 2021-07-16 |
| AU2019346635A1 (en) | 2021-05-20 |
| IL281946A (en) | 2021-05-31 |
| EA202190879A1 (ru) | 2021-08-16 |
| JP7576539B2 (ja) | 2024-10-31 |
| WO2020069322A1 (en) | 2020-04-02 |
| AU2025204027A1 (en) | 2025-06-19 |
| BR112021005913A2 (pt) | 2021-06-29 |
| KR102842377B1 (ko) | 2025-08-06 |
| US20210403476A1 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190879A1 (ru) | Модуляторы ионных каналов | |
| MX2025001282A (es) | Moduladores de los canales ionicos | |
| SA522432719B1 (ar) | مُنظِمات قناة أيونية | |
| EP4397308A3 (en) | Compounds and their methods ofuse | |
| EP4671248A3 (en) | Formulations of ion channel modulators and methods of preparation and use of ion channel modulators | |
| EA201991142A1 (ru) | Варианты il-2 для лечения аутоиммунных заболеваний | |
| EA201991553A1 (ru) | (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды | |
| PH12018502258A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| PH12018501288A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
| EA201891565A1 (ru) | Соединения и композиции для лечения состояний, ассоциированных с активностью sting | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| MY184882A (en) | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors | |
| EA202090555A1 (ru) | Фармацевтические композиции, содержащие антитела к бета-амилоиду | |
| RU2018115781A (ru) | Условно активные полипептиды | |
| MX383833B (es) | Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. | |
| MX2010010303A (es) | Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801. | |
| EA201991898A1 (ru) | Двойные ингибиторы magl и faah | |
| MX2020005545A (es) | Compuestos para el tratamiento de trastornos neuromusculares. | |
| EA201991306A1 (ru) | Соединения и способы их применения | |
| ZA202002936B (en) | Phenoxy acids for the treatment of neuromuscular disorders | |
| EA201590379A1 (ru) | Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| PH12020552172A1 (en) | Cyclic dinucleotides as sting agonists | |
| JOP20240148A1 (ar) | مركب خاص بمستقبل Wnt وطريقة متعلقة به |